Key statistics
As of last trade Poseida Therapeutics Inc (PSTX:NSQ) traded at 3.46, -19.09% below its 52-week high of 4.27, set on Mar 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.61 |
---|---|
High | 3.61 |
Low | 3.31 |
Bid | 3.45 |
Offer | 3.46 |
Previous close | 3.61 |
Average volume | 428.45k |
---|---|
Shares outstanding | 97.12m |
Free float | 70.18m |
P/E (TTM) | -- |
Market cap | 350.60m USD |
EPS (TTM) | -1.19 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 18:21 BST.
More ▼
- Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma
- Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting
- Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma
- Poseida Therapeutics to Present at Upcoming Investor Conferences
- Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024
- Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum
More ▼